The Centers for Medicare & Medicaid Services is accepting comments through Aug. 11 on whether to establish a national Medicare coverage policy for monoclonal antibodies to treat Alzheimer’s disease.

The Food and Drug Administration recently approved the first such drug (aducanumab) through an accelerated pathway that requires the company to verify clinical benefit in a post-approval trial. Medicare administrative contractors are currently making coverage determinations for aducanumab at the local level.

Stakeholders may register for CMS webinars July 22 to learn more or comment. CMS plans to release a proposed decision within six months and a final decision within nine months. 

Related News Articles

Blog
Post-acute care (PAC) providers continue to play a central role in COVID-19 response and recovery. In particular, providers in COVID-19 hotspots have been…
Headline
The Centers for Medicare & Medicaid Services yesterday proposed repealing a final rule codifying how it defines “reasonable and necessary” coverage…
Headline
The House Ways and Means Committee today started its budget reconciliation markup of the Build Back Better Act, which will consider a number of health…
Headline
The Centers for Medicare & Medicaid Services by Nov. 1 will begin reprocessing claims for outpatient clinic visit services provided at excepted off-campus…
Headline
The Medicare Hospital Insurance Trust Fund will have sufficient funds to pay full benefits until 2026, according to the latest annual report released Aug. 31…
Headline
The AHA Aug. 30 urged the Centers for Medicare & Medicaid Services to maintain a focus on accountable and innovative health care over the next decade and…